Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PON1 | P27169 | 1/20 | 0.42 |
| ▸ | NQO1 | P15559 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vadimezan SCHEMBL29363732 | 1.00 | STING1 (1.00) | STING1GLASMN1; SMN2KDM4EMCL1 | |
| Vadimezan SCHEMBL29356696 | 1.00 | STING1 (1.00) | STING1GLASMN1; SMN2KDM4EMCL1 | |
| Vadimezan SCHEMBL4282930 | 0.99 | STING1 (0.97) | STING1GLASMN1; SMN2KDM4EMCL1 | |
| Vadimezan SCHEMBL4282923 | 0.99 | STING1 (0.97) | STING1GLASMN1; SMN2KDM4EMCL1 | |
| SCHEMBL13025119 | 0.89 | GLA (0.81) | STING1GLASMN1; SMN2KDM4EMCL1 | |
| SCHEMBL19209663 | 0.88 | GLA (0.79) | STING1GLASMN1; SMN2KDM4EMCL1 | |
| SCHEMBL20762991 | 0.88 | STING1 (0.79) | STING1GLASMN1; SMN2KDM4ETDP1 | |
| SCHEMBL20845573 | 0.88 | GLA (0.79) | STING1GLASMN1; SMN2KDM4EMCL1 | |
| SCHEMBL8280464 | 0.88 | GLA (0.79) | STING1GLASMN1; SMN2KDM4EMCL1 | |
| SCHEMBL9381286 | 0.87 | STING1 (0.78) | STING1GLASMN1; SMN2KDM4EMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2669 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617812-B2 | Platinum(IV) complexes, methods of manufacture, compositions containing, and methods of use thereof | CITY UNIVERSITY OF HONG KONG (HK) | 2026-05-05 | — | — | US | claimed |
| US-12397047-B2 | Bacteria-derived vesicles and uses thereof | EXOCURE SWEDEN AB (SE) | 2025-08-26 | — | — | US | claimed |
| US-20250186486-A1 | POTENTIATION OF DURABLE ANTITUMOR IMMUNITY BY MULTIFACTORIAL IMMUNE MODULATION | BAYLOR COLLEGE OF MEDICINE (US) | 2025-06-12 | — | — | US | claimed |
| US-20250186623-A1 | EXPRESSION SYSTEM FOR THE TREATMENT OF CANCER | FUNDACION PARA LA INVESTIGACION MEDICA APLICADA (ES) | 2025-06-12 | — | — | US | claimed |
| US-20250188143-A1 | COMBINED GENE AND RADIO THERAPY FOR THE TREATMENT OF CANCER | FUNDACION PARA LA INVESTIGACION MEDICA APLICADA (ES) | 2025-06-12 | — | — | US | claimed |
| US-20250127790-A1 | COMBINATION THERAPY USING VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC | 2025-04-24 | — | — | US | claimed |
| WO-2025080869-A1 | PANCREATIC CANCER IMMUNOTHERAPY USING CATIONIC LIPID AND POLYMER NANOCARRIERS FOR CO-DELIVERY OF KRAS NEOANTIGENS AND STING AND/OR OTHER IMMUNOMODULATORS TO BOOST THE CANCER IMMUNITY CYCLE AND TREAT LIVER METASTASIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-04-17 | — | — | WO | claimed |
| WO-2025076039-A1 | CHLAMYDIAL PROTEASE-LIKE ACTIVITY FACTOR AND ADJUVANT COMPOSITIONS AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2025-04-10 | — | — | WO | claimed |
| WO-2025076210-A1 | CHLAMYDIA VACCINE COMPOSITIONS | VAXCYTE, INC. (US) | 2025-04-10 | — | — | WO | claimed |
| EP-4489795-A1 | EXPRESSION SYSTEM FOR THE TREATMENT OF CANCER | Fundación para la Investigación Médica Aplicada (ES) | 2025-01-15 | — | — | EP | claimed |
| EP-1189611-A4 | CANCER THERAPY | CANCER RES VENTURES LTD (GB) | 2003-05-02 | — | — | EP | claimed |
| US-20030003092-A1 | Cancer therapy | KRISSANSEN GEOFFREY W (NZ) | 2003-01-02 | — | — | US | claimed |
| US-6495585-B2 | Method for treating hyperproliferative tissue in a mammal | HEALTH RESEARCH, INC. | 2002-12-17 | — | — | US | claimed |
| US-20020128303-A1 | Method for treating hyperproliferative tissue in a mammal | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-09-12 | — | — | US | claimed |
| EP-1238666-A2 | Use of xanthenone-4-acetic acid in the manufacture of a medicament in the treatment of hyperproliferative disorders | HEALTH RESEARCH, INC. (US) | 2002-09-11 | — | — | EP | claimed |
| EP-1189611-A1 | CANCER THERAPY | Cancer Research Ventures Limited (GB) | 2002-03-27 | — | — | EP | claimed |
| WO-2002009700-A1 | CANCER TREATMENT BY COMBINATION THERAPY | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-02-07 | — | — | WO | claimed |
| US-20010027210-A1 | Combination therapy for cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2001-10-04 | — | — | US | claimed |
| WO-2000076497-A1 | CANCER THERAPY | CANCER RESEARCH VENTURES LIMITED (GB) | 2000-12-21 | — | — | WO | claimed |
| US-5281620-A | Alkyl substituted xanthenone-4-acetic acid | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1994-01-25 | — | — | US | claimed |